The estimated Net Worth of Charles E Koob is at least $754 Mille dollars as of 22 January 2020. Mr. Koob owns over 15,000 units of MiMedx Inc stock worth over $92,850 and over the last 14 years he sold MDXG stock worth over $429,131. In addition, he makes $232,000 as Director at MiMedx Inc.
Sign up
Mr. Koob MDXG stock SEC Form 4 insiders trading
Charles has made over 4 trades of the MiMedx Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of MDXG stock worth $18,000 on 22 January 2020.
The largest trade he's ever made was selling 50,486 units of MiMedx Inc stock on 13 March 2017 worth over $429,131. On average, Charles trades about 3,772 units every 75 days since 2010. As of 22 January 2020 he still owns at least 15,000 units of MiMedx Inc stock.
You can see the complete history of Mr. Koob stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Koob biography
Charles E. Koob serves as Director of the Company. In 2007, Mr. Koob retired as a partner in the law firm of Simpson Thacher & Bartlett, LLP. While at that firm, Mr. Koob was the co-head of the Litigation Department and served on the firm’s Executive Committee. Mr. Koob specialized in competition, trade regulation and antitrust issues. Throughout his 37-year tenure, he represented clients before the Federal Trade Commission, the Antitrust Division of the Department of Justice, and numerous state and foreign competition authorities. He received his B.A. from Rockhurst College in 1966 and his J.D. from Stanford Law School in 1969. Mr. Koob serves on the board of Stanford Hospital and Clinics. He previously served on the board of a private drug development company and MRI Interventions (OTCBB: MRIC), a publicly traded medical device company. Mr. Koob has served on the Board since 2008 and was nominated as a director due to his extensive legal expertise in representing both publicly traded and privately held businesses.
What is the salary of Charles Koob?
As the Director of MiMedx Inc, the total compensation of Charles Koob at MiMedx Inc is $232,000. There are 13 executives at MiMedx Inc getting paid more, with Timothy Wright having the highest compensation of $5,069,350.
How old is Charles Koob?
Charles Koob is 75, he's been the Director of MiMedx Inc since 2008. There are 1 older and 21 younger executives at MiMedx Inc. The oldest executive at MiMedx Group, Inc is Neil Yeston, 77, who is the Independent Director.
What's Charles Koob's mailing address?
Charles's mailing address filed with the SEC is C/O MIMEDX GROUP, INC., 1775 WEST OAK COMMONS COURT, NE, MARIETTA, GA, 30062.
Insiders trading at MiMedx Inc
Over the last 15 years, insiders at MiMedx Inc have traded over $15,165,698 worth of MiMedx Inc stock and bought 1,553,718 units worth $4,191,559 . The most active insiders traders include Fund Management Ltd.Okumus ..., Steve Gorlin e Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of $487,865. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth $162,029.
What does MiMedx Inc do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
What does MiMedx Inc's logo look like?
Complete history of Mr. Koob stock trades at MiMedx Inc e ClearPoint Neuro Inc
MiMedx Inc executives and stock owners
MiMedx Inc executives and other stock owners filed with the SEC include:
-
Timothy Wright,
Chief Executive Officer, Director -
Peter Carlson,
Chief Financial Officer -
Timothy R. Wright,
CEO & Director -
Dr. Robert Benjamin Stein M.D., Ph.D.,
Exec. VP of R&D -
Peter Martin Carlson CPA,
Chief Financial Officer -
William F. Hulse IV,
Gen. Counsel & Sec. -
Scott Turner,
Senior Vice President - Operations and Procurement -
Dr. Rohit Kashyap Ph.D.,
Exec. VP & Chief Commercial Officer -
Charles Evans,
Independent Director -
Neil Yeston,
Independent Director -
M. Kathleen Behrens Wilsey,
Independent Chairman of the Board -
James Bierman,
Independent Director -
K. Todd Newton,
Independent Director -
Charles Koob,
Director -
Jack Howarth,
Senior Vice President of Investor Relations -
Robert Stein,
Executive Vice President - Research and Development -
Rohit Kashyap,
Executive Vice President, Chief Commercial Officer -
Martin Sutter,
Independent Director -
William Hawkins,
Independent Director -
William Phelan,
Senior Vice President, Chief Accounting Officer -
William Hulse,
General Counsel, Secretary -
Mark Graves,
Chief Compliance Officer -
Scott M. Turner,
Sr. VP of Operations & Procurement -
Stan Micek,
Sr. VP of Bus. Devel. & Portfolio Management -
Dr. David H. Mason Jr.,
Chief Medical Officer -
Hilary Dixon,
VP of Investor Relations & Corp. Communications -
John J. Howarth,
Sr. VP of Investor Relations -
William L. Phelan,
Sr. VP & Chief Accounting Officer -
Larry W Papasan,
Director -
William Charles Taylor,
President and COO -
Michael J. Senken,
Chief Financial Officer -
Joseph G Bleser,
Director -
Parker H Petit,
Chairman & CEO -
J Terry Dewberry,
Director -
Bruce Hack,
Director -
Luis A Aguilar,
Director -
Fund 2 Holding Company, L.P...,
-
Mark Landy,
EVP & Chief Strategy Officer -
Fund Management Ltd.Okumus ...,
-
Edward Borkowski,
EVP & Interim CFO -
Tiffany Olson,
Director -
Kurt M Eichler,
Director -
Thomas J Koob,
Chief Scientific Officer -
Roberta L Mccaw,
General Counsel and Secretary -
Steve Gorlin,
Director -
Rebeccah Covert Brown,
-
Michael J Giuliani,
Director -
Cato T Laurencin,
Director -
M Kathleen Behrens,
Director -
Richard Barry,
Director -
Joseph H Capper,
Chief Executive Officer -
Phyllis Gardner,
Director -
Ricci S Whitlow,
Chief Operating Officer -
Todd Newton,
Director -
Rice Doug,
Chief Financial Officer -
Dorothy E Puhy,
Director